ALR Technologies

ALR Technologies operates at the intersection of human and animal health, providing technology-enabled solutions for chronic disease management. Its core offering is the ALRT Diabetes Solution, an FDA-cleared, HIPAA-compliant remote care management platform that collects data from glucose meters and CGMs, features a patent-pending Predictive A1C algorithm, and includes FDA-cleared insulin dose adjustment tools. The company has expanded into the veterinary market with the GluCurve Pet CGM, which it is preparing to relaunch in Canada, and trades publicly on the OTCQB market under the ticker ALRTF.

An FDA-cleared, HIPAA-compliant data management and remote care platform that collects glucose data from meters and CGMs, processes it with proprietary algorithms (including Predictive A1C), and provides clinical decision support for therapy optimization, enabling active patient management by healthcare providers.

Total raised: $2.5M

In human health, ALRT competes with large diabetes tech companies (e.g., Dexcom, Abbott) and digital health apps by focusing on FDA-cleared clinical tools for providers. In animal health, it claims a first-mover advantage with the first dedicated pet CGM system, competing primarily against traditional and inconvenient blood glucose monitoring methods.